CN109414502A - 治疗炎症性肠病的方法 - Google Patents

治疗炎症性肠病的方法 Download PDF

Info

Publication number
CN109414502A
CN109414502A CN201780041382.4A CN201780041382A CN109414502A CN 109414502 A CN109414502 A CN 109414502A CN 201780041382 A CN201780041382 A CN 201780041382A CN 109414502 A CN109414502 A CN 109414502A
Authority
CN
China
Prior art keywords
vedolizumab
patient
antibody
dose
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780041382.4A
Other languages
English (en)
Chinese (zh)
Inventor
马里亚·罗萨里奥
莫里斯·巴罗卡斯
马克·R·加斯东瓜伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN109414502A publication Critical patent/CN109414502A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201780041382.4A 2016-06-12 2017-06-12 治疗炎症性肠病的方法 Pending CN109414502A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349026P 2016-06-12 2016-06-12
US62/349,026 2016-06-12
PCT/US2017/037072 WO2017218434A1 (en) 2016-06-12 2017-06-12 Method of treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CN109414502A true CN109414502A (zh) 2019-03-01

Family

ID=59270123

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780041382.4A Pending CN109414502A (zh) 2016-06-12 2017-06-12 治疗炎症性肠病的方法

Country Status (7)

Country Link
US (1) US11389533B2 (https=)
EP (1) EP3468597A1 (https=)
JP (1) JP7202893B2 (https=)
CN (1) CN109414502A (https=)
CA (1) CA3027286A1 (https=)
MA (1) MA45245A (https=)
WO (1) WO2017218434A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
CA3223332A1 (en) * 2021-06-17 2022-12-22 Prometheus Laboratories Inc. Systems and methods for improved targeted therapy
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533959A (zh) * 2011-05-02 2014-01-22 米伦纽姆医药公司 抗α4β7抗体的制剂
CN103608071A (zh) * 2011-05-02 2014-02-26 米伦纽姆医药公司 抗α4β7抗体的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
JPWO2002078779A1 (ja) 2001-03-27 2004-07-22 日本ゼオン株式会社 医療用ガイドワイヤ
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
HK1245129A1 (zh) 2015-06-08 2018-08-24 University Of Washington 治疗腹腔疾病的组合物及方法
BR112018068625A2 (pt) 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
IL261750B2 (en) 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533959A (zh) * 2011-05-02 2014-01-22 米伦纽姆医药公司 抗α4β7抗体的制剂
CN103608071A (zh) * 2011-05-02 2014-02-26 米伦纽姆医药公司 抗α4β7抗体的制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M ROSARIO等: "Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn"s disease", 《ALIMENT PHARMACOL THER》 *
佚名: "FDA批准消化系统用药Vedolizumab上市", 《中国执业药师》 *
刘爱玲等: "英夫利西单抗治疗炎症性肠病失应答", 《协和医学杂志》 *
江学良: "解读非住院溃疡性结肠炎患者内科治疗临床实践指南——多伦多共识", 《中华消化病与影像杂志(电子版)》 *

Also Published As

Publication number Publication date
US11389533B2 (en) 2022-07-19
EP3468597A1 (en) 2019-04-17
JP2019519544A (ja) 2019-07-11
CA3027286A1 (en) 2017-12-21
MA45245A (fr) 2019-04-17
US20190255172A1 (en) 2019-08-22
JP7202893B2 (ja) 2023-01-12
WO2017218434A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
JP7723649B2 (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用方法
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
JP5954916B1 (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
KR20220162819A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AU2010335950A1 (en) Method for decreasing immunogenicity
AU2018341959B2 (en) Anti-PACAP antibody
CN109414502A (zh) 治疗炎症性肠病的方法
CN113574071B (zh) 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
JP2023113655A (ja) 小児の障害を処置する方法
BR112021007092A2 (pt) método para o tratamento de miastenia grave
CN112079922B (zh) 抗人p40蛋白域抗体及其用途
HK1254295A1 (zh) 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
KR20210140780A (ko) 건선성 관절염 대상체의 치료 방법
WO1999015200A1 (fr) COMPOSITION MEDICINALE DONT LE PRINCIPE ACTIF EST UN INHIBITEUR DE LIAISON DE gp34
US20230340140A1 (en) Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
RU2778567C2 (ru) Способ лечения педиатрических расстройств/заболеваний
KR20250075690A (ko) 비활성 또는 만성 갑상선 눈 질환의 치료 방법
WO2026086834A1 (zh) 抗ox40抗体在治疗皮炎疾病中的用途
TW202448933A (zh) 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
JP2023527476A (ja) 精神症性疾患の処置に使用するための抗ｈｅｒｖ－ｗエンベロープタンパク質抗体
HK40061358A (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220128

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts

Applicant before: MILLENNIUM PHARMACEUTICALS, Inc.